Description: Ampio Pharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, engages in the discovery and development of pharmaceutical drugs and diagnostic products to identify, treat, and prevent metabolic disorders, eye diseases, kidney diseases, acute and chronic inflammation diseases, and male sexual dysfunction. Its products include Ampion, a non-steroidal anti-inflammatory biologic to treat inflammatory conditions and autoimmune diseases; Optina, an orally administered danazol for the treatment of diabetic macular edema; Vasaloc for the treatment of diabetic nephropathy; and Zertane, an oral drug for treating male sexual dysfunction to premature ejaculation, which is under Phase III clinical trial. The company is also developing a handheld oxidation-reduction potential diagnostic device for use at home or in healthcare facilities that will measure the oxidants/antioxidant balances in human blood and plasma; and methylphenidate derivatives for cancer, which are in pre-clinical development. Ampio Pharmaceuticals, Inc. is headquartered in Greenwood Village, Colorado.
Home Page: www.ampiopharma.com
AMPE Technical Analysis
373 Inverness Parkway
Englewood,
CO
80112
United States
Phone:
720 437 6500
Officers
Name | Title |
---|---|
Mr. Michael A. Martino | CEO & Director |
Dr. David Bar-Or M.D. | Founder & Chairman of Scientific Advisory Board |
Mr. Daniel G. Stokely CPA, CPA | CFO, Corp. Sec. & Treasurer |
Dr. Howard Levy M.B.B.Ch., M.M.M., Ph.D. | Chief Medical Officer |
Lane Hapke | VP of Manufacturing Operations |
April Ramirez | Clinical Trial Mang. |
Laura Goldberg | VP of Quality and Regulatory Operations |
Exchange: NYSE MKT
Country: US : United States of America
Currency: US Dollar ($)
GIC Sector: | Health Care |
---|---|
GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
GIC Industry: | Pharmaceuticals |
GIC Sub-Industry: | Pharmaceuticals |
Forward PE: | 0 |
---|---|
Trailing PE: | 0 |
Price-to-Book MRQ: | 0.2989 |
Price-to-Sales TTM: | 0 |
IPO Date: | 2010-03-31 |
Fiscal Year End: | December |
Full Time Employees: | 9 |